Dbv Technologies Phone Number

Filter Type: All Time (47 Results) Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Dbv technologies Phone Number

908-679-5200Corporate Headquarters U.S. (DBV Technologies Inc.) Summit 25 DeForest Avenue, Suite 203 Summit, NJ 07901, USA Phone: +1 908-679-5200

Updated: 4 hours ago / PreviewShow details

DBV Technologies’s headquarters are in GREEN Sq - BATIMENT D, Bagneux, Ile-de-France, 92220, France What is DBV Technologies’s phone number? DBV Technologies’s phone number is +33 1 55 42 78 78

Employees: 104
Phone: 01 55 42 78 78
Location: GREEN Sq-BATIMENT D, Bagneux, 92220, Ile-de-France

Updated: 6 hours ago / PreviewShow details

Contact Email [email protected]dbv-technologies.com. Phone Number +33 (0)1 55 42 78 78. DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of

Updated: 6 hours ago / PreviewShow details

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a journey to advance epicutaneous immunotherapy, using our innovative technology platform, Viaskin™.

Updated: 3 hours ago / PreviewShow details

Find contact information for DBV Technologies. Learn about their Business Services market share, competitors, and DBV Technologies's email format.

Employees: 104
Phone: 01 55 42 78 78
Location: GREEN Sq-BATIMENT D, Bagneux, 92220, Ile-de-France

Updated: 1 hours ago / PreviewShow details

About DBV. DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic

Updated: 3 hours ago / PreviewShow details

Instead, DBV Technologies spent most of 2021 convincing its shareholders this wouldn't be the case. With this in mind, it's probably best to avoid this biotech stock for the foreseeable future. 10

Updated: 5 hours ago / PreviewShow details

Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at

Updated: 4 hours ago / PreviewShow details

DBV Technologies 2018 - 2020 2 years. Summit, NJ Contact Jun directly Join to view full profile People also viewed David Chapman Vice President, Market Access at Agios Pharmaceuticals

Title: Head - Market Access Pricing …
Location: Cambridge, Massachusetts, United States
Connections: 419

Updated: 3 hours ago / PreviewShow details

Quillbot key technologies used on the website. Check the section to learn more about which tools and technologies are used by Quillbot and how much is Quillbot oriented towards technology. Quillbot Frequently Asked Questions. Phone number finder Blog …

Updated: 2 hours ago / PreviewShow details

(401) 714-3803DBV Technology, LLC. 376 Dry Bridge Rd STE C1 North Kingstown, RI 02852 [email protected]dbvtechnology.com (401) 714-3803

Updated: 2 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak . DBV Technologies +1 857-529-2363 . [email protected]dbv-technologies.com . Media Contact Angela Marcucci . DBV Technologies +1 646-842-2393 . [email protected]dbv-technologies.com

Updated: 2 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com.

Updated: 4 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela …

Updated: 1 hours ago / PreviewShow details

Nous utilisons des cookies techniques nécessaires au bon fonctionnement du site internet. Si vous y consentez, nous et nos partenaires utiliserons également des cookies et autres traceurs de mesure d’audience, de publicité et de réseaux sociaux, dont le détail des finalités est accessible depuis le bouton « Gérer les paramètres ».

Updated: 4 hours ago / PreviewShow details

Dec 22, 2021 10:00AM EST. S hares of DBV Technologies SA ( NASDAQ: DBVT) tanked 48.5% to close at $1.39 on Tuesday after the company announced its decision to withdraw the Marketing Authorization

Updated: Just Now / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela …

Updated: 1 hours ago / PreviewShow details

Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat …

Updated: 7 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com.

Updated: 3 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com.

Updated: 5 hours ago / PreviewShow details

DBV Technologies General Information Description. DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets.

Updated: 7 hours ago / PreviewShow details

DBV Technologies S.A. Analyst Report: Eli Lilly and Company Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key …

Updated: 6 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com.

Updated: 2 hours ago / PreviewShow details

Montrouge, France, January 7, 2022. DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat …

Updated: 9 hours ago / PreviewShow details

857-529-2363Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv

Updated: 9 hours ago / PreviewShow details

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against DBV Technologies S.A. – DBVT New York, N.Y., January 15, 2019. Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of DBV Technologies S.A. (NASDAQ: DBVT) from February 14, 2018

Updated: 2 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 [email protected]dbv-technologies.com

Updated: 8 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela …

Updated: 8 hours ago / PreviewShow details

DBV Technologies: Still Poised for a Triple-Digit Upside. Shares of DBV Technologies SA ( NASDAQ: DBVT) tanked 48.5% to close at $1.39 on Tuesday after the company announced its decision to withdraw the Marketing Authorization Application (MAA) that it had earlier submitted to the European Medicines Agency (EMA) for the Viaskin Peanut patch.

Updated: 4 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com

Updated: 7 hours ago / PreviewShow details

DBV Technologies (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, "DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and …

Updated: Just Now / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected] Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]

Updated: 5 hours ago / PreviewShow details

PRIVACY POLICY. Last update: November 2021. The website www.dbv-technologies.com (hereinafter the “ Website ”), published by the company DBV Technologies (hereinafter “ DBV Technologies ”), is the corporate website of DBV Technologies presenting in particular its products.. While you are accessing, browsing, navigating and using the Website and its …

Updated: 5 hours ago / PreviewShow details

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France.DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood.Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug …

Updated: 6 hours ago / PreviewShow details

DBV Technologies has a 12 month low of $2.45 and a 12 month high of $7.38. DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Tuesday, October 26th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.29) by $0.07. The firm had revenue of $1.32 million for the quarter, compared to

Updated: 1 hours ago / PreviewShow details

DBV Technologies has 141 employees across 4 locations and $11.28 M in annual revenue in FY 2020. See insights on DBV Technologies including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Updated: 3 hours ago / PreviewShow details

646-842-2393Media Contact Angela Marcucci DBV Technologies +1 646-842-2393 [email protected]dbv-technologies.com. 1 The Company’s unaudited consolidated financial statements for the quarter ended March 31,

Updated: 8 hours ago / PreviewShow details

Should you have any questions, you may directly contact DBV Technologies by sending an email to [email protected]dbv-technologies.com. 2. INTELLECTUAL PROPERTY RIGHTS. The Website and all its elements or which are made available to Users, in particular trademarks, logos, photographs, programs, source codes, data, databases, animated or non-animated images

Updated: 2 hours ago / PreviewShow details

(315) 542-7878How can I contact DBV Technologies? DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120 . The company can be reached via phone at (315) 542-7878 , via email at [email protected] , …

Updated: 6 hours ago / PreviewShow details

Montrouge, France, December 20, 2021. DBV Technologies Provides Update on Investigational Viaskin Peanut DBV Technologies S.A. ( DBVT ), a clinical-stage biopharmaceutical company, today announced plans to initiate a new, pivotal Phase 3 clinical study for a modified Viaskin Peanut patch in children in the intended patient population.

Updated: 2 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela …

Updated: 8 hours ago / PreviewShow details

Gainers DBV Technologies S.A. (NASDAQ: DBVT) rose 20.3% to $3.68 in pre-market trading after declining 15% on Thursday. DBV Technologies, disclosed that …

Updated: 1 hours ago / PreviewShow details

DBV will host a conference call and live audio webcast on Monday, December 20, 2021, at 5:00 p.m. ET to provide an update on investigational Viaskin Peanut. This call is accessible via the below

Updated: 6 hours ago / PreviewShow details

857-529-2363Investor Contact Anne Pollak DBV Technologies +1 857-529-2363 [email protected]dbv-technologies.com. Media Contact Angela …

Updated: 5 hours ago / PreviewShow details

(866) 939-3921DBV will host a conference call and live audio webcast on Monday, December 20, 2021, at 5:00 p.m. ET to provide an update on investigational Viaskin Peanut. This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50269344. United States: (866) 939-3921. Canada: (866) 215-5508.

Updated: 3 hours ago / PreviewShow details

Energy Smart Insulation's Agricultural Spray Foam Insulation is used to insulate Chicago's Ag buildings and poultry houses. FF88 is unique because of its unmatched level of performance both as a fire retardant (prevents flame spread/flashover) and as a fire resistant (resists fire penetration). Energy Smart Insulation.

Updated: 1 hours ago / PreviewShow details

DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist. Why DBV Technologies Stock Is …

Updated: 9 hours ago / PreviewShow details

Filter Type:All Time (47 Results) Past 24 Hours Past Week Past month

Please leave your comments here:

New Contact Number

Frequently Asked Questions

Where can i contact dbdbv technologies?

DBV Technologies Locations. Headquarters. Paris. 177-181 avenue Pierre Brossolette. 92120 – Montrouge, France. Phone: +33 (0)1 55 42 78 78. New York. 12 East 49th Street.

Who is behind dbv technologies?

History. DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology ), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris). The founders provided initial startup capital.

What does dbvt stand for?

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference.

What is dbv viaskin technology?

About DBV Technologies DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin.

Popular Search

Dating
Digiop